Dow Up1.32% Nasdaq Up1.60%

Celldex Therapeutics, Inc. (CLDX)

15.41 0.90(6.20%) Oct 23, 4:00PM EDT
ProfileGet Profile for:
Celldex Therapeutics, Inc.
Perryville III Building
53 Frontage Road
Hampton, NJ 08827
United States - Map
Phone: 908-200-7500
Fax: 908-454-1911

Index Membership:N/A
Full Time Employees:120

Business Summary 

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011) is a targeted antibody-drug conjugate in a randomized study for the treatment of triple negative breast cancer. The company also has various earlier stage drug candidates in clinical development, including varlilumab (CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. The company has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; and Bristol-Myers Squibb Company. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Celldex Therapeutics, Inc.

Corporate Governance 
Celldex Therapeutics, Inc.’s ISS Governance QuickScore as of Oct 1, 2014 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 7; Compensation: 5.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Anthony S. Marucci M.B.A., 52
Chief Exec. Officer, Pres and Director
Dr. Tibor Keler Ph.D., 55
Founder, Chief Scientific Officer and Exec. VP
Mr. Avery W. Catlin , 66
Chief Financial Officer, Principal Accounting Officer, Sr. VP, Treasurer and Sec.
Dr. Thomas Davis M.D. , 50
Chief Medical Officer and Exec. VP
Dr. Ronald A. Pepin Ph.D., 58
Chief Bus. Officer and Sr. VP
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders